Is the dog owner at fault? Or the little girl, or the airline? It turns out there’s a really easy answer.

Bargain stock hunters have honed in their attention of late on shares of Puma Biotechnology, Inc. (NYSE:PBYI). The stock is currently valued at $68.25 after moving 3.17% in the most recent session and 0.22% over the past 5 trading days. Given that the stock is priced cheaply, let’s take a look and see if …

Digital marketing blogs may be numerous, but I find them still to be critical. I’ve been in digital marketing for over 20 years, and the only way you can stay relevant that long is to read A LOT. In digital marketing, if you don’t learn, you die. Period. Members of the Convince & Convert team …
Read Article: Jay Baer’s Top 30 Digital Marketing Blogs

With the Olympic Games concluding this week in South Korea, the pomp and circumstances in Pyeongchang are certainly emblematic of the country’s place as an influencer on the global stage. However, the country has focused on more than winter sports these last few years. They have also developed a golden biotech industry focused on strong …
Read Article: Highlighting History: South Korea Goes for Biotech Gold

Over the last decade, I’ve become increasingly conscious of maintaining my cardiovascular health, making dietary changes and keeping my blood pressure and cholesterol levels in check. Heart disease is preventable and taking sensible steps can help a person dodge the number one killer in our country. It’s true that heart disease kills more Americans than …
Read Article: Innovation (at Home and in the Lab) Can Reduce Your Heart-Attack Risk

It is an underreported fact that the time it takes for a generic medicine to come to market has remained steady at approximately 13.5 years for over two decades. And, once entering the market, generics are acquiring greater market share, faster than ever before. That’s why BIO is releasing its a new infographic, which highlights the …
Read Article: New Infographic: Balancing Need for Innovation with Competition

On Feb 5th $CORT tanked over 20% after Teva announced they were submitting an ANDA for CORT’s drug, Korlym (mifepristone). I can’t find absolutely anything on a Teva trial to show bioequivalence to Korlym. I can’t even find any single webpage that ties Teva to Korlym outside of the websites that announced the Feb 5th …
Read Article: How can Teva submit an ANDA for Korlym without bioequivalence data gathered by Teva? There doesn’t seem to be any indication they did so?

As biotechnology continues to drive advancement in the way we grow and consume food, consumer skepticism around biotechnology remains steady. As I alluded to in Science Over Fiction: GMOS for Public Good, consumer skepticism is largely derived from misconceptions around the science behind biotechnology. For example, take the following survey results as noted in a …
Read Article: Gene-Editing: How Do We Move Towards Acceptance

Puma Biotechnology logo Dupont Capital Management Corp purchased a new stake in Puma Biotechnology Inc (NASDAQ:PBYI) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 5,977 shares of the …